Physician research rivals ImpactRx and TargetRx merge
Gregory Ellis (pictured), who was recently appointed CEO of ImpactRx by its new owners Symphony Technology Group, will lead the merged business.
TargetRx launched in 1999 and works principally with pharmaceutical and biotech firms to help them understand the drivers of product choice and brand adoption among doctors. Its CEO is Craig Scott.
ImpactRx, meanwhile, maintains panels of physicians to monitor the effect that product promotions have on their prescribing behaviour.
Ellis said: “Together, we will provide our clients with an unprecedented level of insight into what physicians do and why they do it.”
We hope you enjoyed this article.
Research Live is published by MRS.
The Market Research Society (MRS) exists to promote and protect the research sector, showcasing how research delivers impact for businesses and government.
Members of MRS enjoy many benefits including tailoured policy guidance, discounts on training and conferences, and access to member-only content.
For example, there's an archive of winning case studies from over a decade of MRS Awards.
Find out more about the benefits of joining MRS here.
0 Comments